Chronic myeloid leukaemia Initial PBS authority application Imatinib mesylate, accelerated or blast phase application Supporting information form (PB082)

You must lodge this form for a patient starting initial PBS subsidised treatment with imatinib mesylate for either accelerated or blast phase of chronic myeloid leukaemia expressing the Philadelphia chromosome or the transcript BCR-ABL tyrosine kinase.

Page last updated: 15 June 2016

This information was printed Tuesday 27 September 2016 from It may not include all of the relevant information on this topic. Please consider any relevant site notices at when using this material.